Akebia Therapeutics
AKBA
$1.34
Share price
0.75%
Change (1 day)
47.25%
Change (1 year)
Categories
Akebia Therapeutics (AKBA) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.27 B
According to Akebia Therapeutics's latest financial reports the company's total liabilities are $0.27 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Akebia Therapeutics - Total liabilities on balance sheet (from 2013 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.27 B | -22.39% |
| 2022-12-31 | $0.35 B | -22.95% |
| 2021-12-31 | $0.45 B | 14.83% |
| 2020-12-31 | $0.39 B | 5.33% |
| 2019-12-31 | $0.37 B | 4.39% |
| 2018-12-31 | $0.36 B | 49.21% |
| 2017-12-31 | $0.24 B | 4.13% |
| 2016-12-31 | $0.23 B | 1843.53% |
| 2015-12-31 | $11.94 M | 72.65% |
| 2014-12-31 | $6.91 M | 76.91% |
| 2013-12-31 | $3.91 M | -20.58% |
| 2012-12-31 | $4.92 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $98.78 B | 36,179.37% | 🇺🇸 USA |
 Novartis NVS | $54.57 B | 19,944.29% | 🇨🇭 Switzerland |
 Amgen AMGN | $90.92 B | 33,291.97% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | $0.26 B | -1.92% | 🇺🇸 USA |